Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
FGEN [NASD]
FibroGen, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-2.13 Insider Own1.30% Shs Outstand91.17M Perf Week-4.50%
Market Cap1.70B Forward P/E- EPS next Y-2.22 Insider Trans-4.01% Shs Float83.64M Perf Month-41.86%
Income-189.30M PEG- EPS next Q-0.80 Inst Own79.40% Short Float10.47% Perf Quarter-56.06%
Sales176.30M P/S9.62 EPS this Y-137.10% Inst Trans4.72% Short Ratio5.48 Perf Half Y-59.05%
Book/sh4.63 P/B4.10 EPS next Y-51.00% ROA-23.10% Target Price- Perf Year-52.14%
Cash/sh7.69 P/C2.47 EPS next 5Y- ROE-43.80% 52W Range18.12 - 57.21 Perf YTD-48.79%
Dividend- P/FCF21.85 EPS past 5Y-8.20% ROI-40.20% 52W High-66.80% Beta1.00
Dividend %- Quick Ratio4.50 Sales past 5Y-0.50% Gross Margin95.00% 52W Low4.83% ATR1.96
Employees599 Current Ratio4.60 Sales Q/Q712.50% Oper. Margin- RSI (14)25.69 Volatility5.13% 6.29%
OptionableYes Debt/Eq0.13 EPS Q/Q43.20% Profit Margin- Rel Volume1.04 Prev Close19.91
ShortableYes LT Debt/Eq0.10 EarningsMar 01 AMC Payout- Avg Volume1.60M Price19.00
Recom2.50 SMA20-31.31% SMA50-49.74% SMA200-54.25% Volume1,655,406 Change-4.60%
Apr-07-21Downgrade Mizuho Buy → Neutral $72 → $29
Apr-07-21Downgrade H.C. Wainwright Buy → Neutral
Mar-31-21Upgrade BofA Securities Neutral → Buy $47
Mar-02-21Downgrade Jefferies Buy → Hold $75 → $45
Feb-01-21Initiated H.C. Wainwright Buy $58
Oct-26-20Initiated Raymond James Underperform
Jul-10-20Resumed Stifel Buy $71
May-01-20Initiated Cowen Market Perform $40
Apr-27-20Initiated BofA/Merrill Neutral $45
May-29-19Resumed Goldman Neutral
May-10-19Downgrade William Blair Outperform → Mkt Perform
Apr-12-19Initiated Piper Jaffray Neutral $65
Feb-11-19Resumed Stifel Buy $71
Dec-19-18Upgrade Citigroup Neutral → Buy
Aug-08-17Reiterated Stifel Buy $38 → $80
Aug-08-17Reiterated Leerink Partners Outperform $52 → $82
Jul-21-17Downgrade Goldman Buy → Neutral
Jul-11-17Initiated Jefferies Buy
Feb-11-16Upgrade Credit Suisse Neutral → Outperform $40
Jan-21-16Initiated Credit Suisse Neutral
Apr-19-21 11:17PM  
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN
PR Newswire
11:03PM  
SHAREHOLDER ALERT: CLAIMSFILER REMINDS CAN, CS, DOX, FGEN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
GlobeNewswire
08:27PM  
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
Newsfile
07:03PM  
FIBROGEN DEADLINE ALERT
Newsfile
06:51PM  
FGEN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving FibroGen, Inc.
Newsfile
05:16PM  
Rosen, Global Investor Counsel, Encourages FibroGen, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline - FGEN
Newsfile
02:58PM  
FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited Shareholders
Newsfile
01:25PM  
Kessler Topaz Meltzer & Check, LLP: Important Deadline Reminder for FibroGen, Inc. Investors in Securities Fraud Class Action Lawsuit
PR Newswire
01:10PM  
INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
ACCESSWIRE
01:00PM  
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN)
Business Wire
12:15PM  
LAWSUITS FILED AGAINST FGEN, DDD and CAN - Jakubowitz Law Pursues Shareholders Claims
ACCESSWIRE
11:00AM  
LAWSUITS FILED AGAINST CYDY, FGEN and DDD - Jakubowitz Law Pursues Shareholders Claims
ACCESSWIRE
11:00AM  
FGEN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds FibroGen, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm
Business Wire
10:05AM  
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed and Investor Deadline Established
PR Newswire
09:08AM  
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
Newsfile
07:40AM  
LAWSUITS FILED AGAINST REGI, CYDY and FGEN - Jakubowitz Law Pursues Shareholders Claims
ACCESSWIRE
06:30AM  
LAWSUITS FILED AGAINST REGI, FGEN and DDD - Jakubowitz Law Pursues Shareholders Claims
ACCESSWIRE
12:40AM  
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
ACCESSWIRE
Apr-17-21 03:49PM  
FGEN EQUITY ALERT: Kessler Topaz Meltzer & Check, LLP Announces that a Securities Fraud Class Action Lawsuit was filed on Behalf of Investors of FibroGen, Inc.
GlobeNewswire
09:00AM  
FIBROGEN INVESTOR ALERT: Shareholder Class Action Lawsuit Filed
ACCESSWIRE
Apr-16-21 10:50PM  
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS DOX, FGEN, GOEV, GOEVW INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
GlobeNewswire
08:00PM  
BREAKING NEWS: ROSEN, A LEADING LAW FIRM, Encourages FibroGen, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline FGEN
GlobeNewswire
07:02PM  
FibroGen Deadline Alert
Newsfile
06:42PM  
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
Newsfile
05:08PM  
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Updates DOX, FGEN Investors on Securities Fraud Lawsuits, Encourages Investors with Losses to Contact the Firm
ACCESSWIRE
03:03PM  
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
Newsfile
01:30PM  
LAWSUITS FILED AGAINST EBIX, PLUG and FGEN - Jakubowitz Law Pursues Shareholders Claims
ACCESSWIRE
12:00PM  
Lawsuits Filed Against EBIX, REGI and FGEN - Jakubowitz Law Pursues Shareholders Claims
ACCESSWIRE
11:00AM  
FGEN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies FibroGen, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm
ACCESSWIRE
10:02AM  
INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Newsfile
09:13AM  
Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc. - FGEN
Newsfile
07:59AM  
FGEN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving FibroGen, Inc.
Newsfile
06:30AM  
LAWSUITS FILED AGAINST VLDR, FGEN and DDD - Jakubowitz Law Pursues Shareholders Claims
ACCESSWIRE
06:30AM  
3 Biotech Stocks Ripe for Spring Portfolio Cleaning
Motley Fool
Apr-15-21 10:05PM  
FIBROGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against FibroGen, Inc. - FGEN
Newsfile
07:33PM  
FGEN CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against FibroGen Inc.
Business Wire
07:12PM  
FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited Shareholders
Newsfile
07:00PM  
FIBROGEN INVESTOR ALERT: Class Action Lawsuit Filed
ACCESSWIRE
05:40PM  
Lawsuits Filed Against VLDR, LDOS and FGEN - Jakubowitz Law Pursues Shareholders Claims
ACCESSWIRE
04:25PM  
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed and Investor Deadline Approaching
ACCESSWIRE
04:00PM  
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
Newsfile
02:31PM  
Portnoy Law: Lawsuit Filed On Behalf of FibroGen, Inc. Investors
GlobeNewswire
02:15PM  
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NEPT, FGEN and DDD
ACCESSWIRE
02:11PM  
SHAREHOLDER ALERT: Robbins LLP Announces That FibroGen, Inc. (FGEN) is Being Sued for Misleading Shareholders
Business Wire
01:45PM  
INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
ACCESSWIRE
01:44PM  
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
PR Newswire
12:45PM  
LAWSUITS FILED AGAINST GOEV, FGEN and DDD - Jakubowitz Law Pursues Shareholders Claims
ACCESSWIRE
11:41AM  
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc.
Business Wire
11:12AM  
FGEN INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Fibrogen Inc.
PR Newswire
11:00AM  
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of GOEV, FGEN and EBON
ACCESSWIRE
10:00AM  
FGEN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies FibroGen, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm
GlobeNewswire
07:00AM  
FibroGen Receives Rare Pediatric Disease Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy
GlobeNewswire
06:30AM  
CLASS ACTION UPDATE for REGI, NEPT and FGEN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
ACCESSWIRE
Apr-14-21 11:29PM  
SHAREHOLDER ALERT: CLAIMSFILER REMINDS DOX, FGEN, GOEV, GOEVW INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
GlobeNewswire
09:00PM  
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ebang, 3D Systems, Amdocs, and FibroGen and Encourages Investors to Contact the Firm
GlobeNewswire
07:10PM  
FibroGen Investor Alert
Newsfile
06:31PM  
FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited Shareholders
Newsfile
05:00PM  
FIBROGEN INVESTOR ALERT: Shareholder Lawsuit Filed
ACCESSWIRE
04:32PM  
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of XL, FGEN and DDD
ACCESSWIRE
04:25PM  
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
ACCESSWIRE
03:30PM  
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of FibroGen Inc. (FGEN) Investors
Business Wire
02:58PM  
FGEN CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc.
PR Newswire
02:50PM  
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of FGEN, DOX and DDD
ACCESSWIRE
02:07PM  
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts FibroGen (FGEN) Investors to Filing of Securities Fraud Class Action and Encourages Investors with Losses to Contact Its Attorneys Now
Newsfile
01:33PM  
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
Newsfile
12:04PM  
LAWSUIT FILED: FibroGen, Inc. Sued for Violations of the Federal Securities Laws; Investors Should Contact Block & Leviton
Newsfile
11:50AM  
LAWSUITS FILED AGAINST FGEN, DOX and DDD - Jakubowitz Law Pursues Shareholders Claims
ACCESSWIRE
11:00AM  
FGEN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies FibroGen, Inc. Shareholders of Class Action and Encourages Shareholders to Contact the Firm
ACCESSWIRE
10:25AM  
SHAREHOLDER ALERT: IQDNX GOEV FGEN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
ACCESSWIRE
09:39AM  
FIBROGEN, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against FibroGen, Inc.
GlobeNewswire
09:30AM  
SHAREHOLDER ALERT: FibroGen, Inc. (FGEN) Officers and Directors Under Investigation for False Statements and Insider Trading
PR Newswire
06:30AM  
CLASS ACTION UPDATE for FGEN, EBON and DOX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
ACCESSWIRE
Apr-13-21 09:00PM  
FIBROGEN ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against FibroGen, Inc. and Encourages Investors to Contact the Firm
Business Wire
09:00PM  
BREAKING NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages FibroGen, Inc. Investors with Losses to Secure Counsel Before Important Deadline - FGEN
PR Newswire
08:37PM  
FIBROGEN SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against FibroGen, Inc. - FGEN
Business Wire
08:16PM  
SHAREHOLDER ALERT: REGI FGEN DDD: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
ACCESSWIRE
07:24PM  
INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
ACCESSWIRE
06:43PM  
Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Filed Against FibroGen, Inc. FGEN
GlobeNewswire
05:48PM  
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against FibroGen, Inc. (FGEN)
GlobeNewswire
05:44PM  
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of MPLN, KRMD and FGEN
ACCESSWIRE
05:00PM  
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of FibroGen Inc. (FGEN) Investors
Business Wire
04:20PM  
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MPLN, KRMD and FGEN
ACCESSWIRE
03:55PM  
Berman Tabacco's California Office Files Securities Class Action Lawsuit Against FibroGen, Inc. (FGEN) And Announces June 11, 2021 Lead Plaintiff Deadline
Newsfile
03:05PM  
CLASS ACTION UPDATE for MPLN, KRMD and FGEN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
ACCESSWIRE
03:00PM  
FGEN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies FibroGen, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm
PR Newswire
02:52PM  
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Business Wire
02:14PM  
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of FibroGen Inc. (FGEN) Investors
Business Wire
11:40AM  
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Announces Filing of Securities Fraud Class Action
ACCESSWIRE
11:00AM  
FGEN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies FibroGen, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm
ACCESSWIRE
09:55AM  
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages FibroGen, Inc. Investors with Losses to Secure Counsel Before Important Deadline FGEN
Business Wire
08:59AM  
FibroGen (FGEN) DMD Drug Pamrevlumab Gets FDA's Fast Track Tag
Zacks
Apr-12-21 03:54PM  
Berman Tabacco Files Securities Class Action Lawsuit Against FibroGen, Inc. (FGEN)
Newsfile +7.11%
10:05AM  
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Company Admits to Manipulating Data for Anemia Drug
GlobeNewswire
07:00AM  
FibroGen Receives Fast Track Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy
GlobeNewswire
Apr-11-21 11:45PM  
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
ACCESSWIRE
Apr-09-21 07:06PM  
Fibrogen Deadline Alert
Newsfile
01:51PM  
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
PR Newswire
10:50AM  
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Company Admits to Manipulating Data for Anemia Drug
Newsfile
Apr-08-21 09:00PM  
FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of FibroGen Stockholders and Encourages Investors to Contact the Firm
Business Wire
07:50PM  
Is Fibrogen Still a Buy Following Data Analysis Faux Pas? Analyst Weighs In
TipRanks
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KEARNS THOMAS F JRDirectorMar 11Option Exercise3.5018,00063,000166,164Mar 15 06:22 PM
KEARNS THOMAS F JRDirectorMar 11Sale35.0218,000630,360148,164Mar 15 06:22 PM
Kurkijarvi KaleviDirectorFeb 17Option Exercise28.656,000171,90039,100Feb 19 07:10 PM
Kurkijarvi KaleviDirectorFeb 17Sale52.406,000314,38333,100Feb 19 07:10 PM
Kurkijarvi KaleviDirectorJan 19Option Exercise19.056,000114,30039,100Jan 21 07:24 PM
Kurkijarvi KaleviDirectorJan 19Sale43.386,000260,28033,100Jan 21 07:24 PM
Kurkijarvi KaleviDirectorJan 14Option Exercise19.055,999114,28139,099Jan 15 08:02 PM
Kurkijarvi KaleviDirectorJan 14Sale40.045,999240,20033,100Jan 15 08:02 PM
Schoeneck James ADirectorJan 04Option Exercise9.786,00058,65015,400Jan 06 07:08 PM
Kurkijarvi KaleviDirectorDec 28Option Exercise18.346,001110,05939,101Dec 30 06:07 PM
Kurkijarvi KaleviDirectorDec 28Sale40.406,001242,45533,100Dec 30 06:07 PM
Yu K PeonyChief Medical OfficerDec 16Sale41.613,350139,394192,292Dec 17 07:06 PM
Cotroneo PatSVP, Finance and CFODec 15Sale43.603,068133,765266,144Dec 17 07:04 PM
Kouchakji EliasSVP, Clinical Dev, Drug SafetyNov 17Option Exercise14.577,082103,220134,495Nov 19 04:52 PM
Yu K PeonyChief Medical OfficerSep 16Sale44.013,351147,478198,934Sep 18 05:19 PM
Cotroneo PatSVP, Finance and CFOSep 15Sale43.633,070133,944272,226Sep 17 06:03 PM
Cotroneo PatSVP, Finance and CFOSep 03Option Exercise23.3015,004349,582293,314Sep 04 04:30 PM
Yu K PeonyChief Medical OfficerSep 03Option Exercise18.0010,000180,000215,576Sep 04 04:33 PM
Yu K PeonyChief Medical OfficerSep 03Sale50.8910,000508,900205,576Sep 04 04:33 PM
Cotroneo PatSVP, Finance and CFOSep 03Sale50.9115,004763,854278,310Sep 04 04:30 PM
Schoeneck James ADirectorAug 20Option Exercise5.956,00035,70015,400Aug 21 05:58 PM
Cotroneo PatSVP, Finance and CFOAug 11Option Exercise18.727,250135,712278,310Aug 11 04:34 PM
Cotroneo PatSVP, Finance and CFOAug 07Option Exercise19.3922,554437,322293,614Aug 11 04:34 PM
Cotroneo PatSVP, Finance and CFOAug 07Sale48.0022,5541,082,592271,060Aug 11 04:34 PM
Yu K PeonyChief Medical OfficerJul 24Sale42.353,351141,915205,576Jul 28 07:33 PM
Cotroneo PatSVP, Finance and CFOJun 16Sale39.683,928155,863271,060Jun 18 06:35 PM
Conterno Enrique AChief Executive OfficerJun 11Buy35.2819,800698,59927,800Jun 12 06:59 AM
Conterno Enrique AChief Executive OfficerJun 10Buy36.298,000290,2828,000Jun 12 06:59 AM
Rosenkranz Roberto PedroDirectorJun 09Option Exercise23.8524,000572,40096,100Jun 11 09:22 PM
open in yahoo | open in reuters | open in marketwatch | open in google
affiliate • advertise • contact • privacy • help
Do not sell my personal information
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2021 FINVIZ.com. All Rights Reserved.